primary antibodies phospho-fak tyr397  (Cell Signaling Technology Inc)

Journal: Acta Biochimica et Biophysica Sinica

Article Title: SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells

doi: 10.3724/abbs.2022008

Figure Lengend Snippet: Inhibitory effects of SY-707 on the phosphorylation of FAK (A,B) Concentration-dependent inhibition of SY-707 on phosphorylation of FAK in T47D (A) and MCF-7 (B) cells. Cells were cultured in 6-well plates and treated with the indicated concentrations of SY-707 for 1 h before stimulation with or without 100 ng/mL IGF1 for 10 min. Control cells received the drug vehicle with 0.1% DMSO. Cell lysates were analyzed by western blot analysis using specific antibodies against p-FAK, p-Pyk2, p-AKT and p-ERK respectively. (C) Concentration-dependent inhibition of SY-707 on phosphorylation of IGF1R in T47D cells. The cells were incubated with SY-707 for 1 h before stimulation with 100 ng/mL IGF1 for 10 min. Control cells received the drug vehicle with 0.1% DMSO. Cell lysates were analyzed by western blot analysis using specific antibodies against p-IGF1R, p-STAT3, p-AKT and p-ERK respectively.

Article Snippet: Primary antibodies against phospho-FAK (3283, 1:1000 dilution), phospho-ERK (4377, 1:2000 dilution), phospho-AKT (4060, 1:2000 dilution), FAK (3285, 1:1000 dilution), AKT (6703, 1:1000 dilution) and β-Actin (5125, 1:10,0000 dilution) were purchased from Cell Signaling Technology (Beverly, USA) and the HRP-conjugated goat anti-rabbit IgG (ZDR-5306, 1:10,000 dilution) was purchased from Jackson (West Grove, USA ).

Techniques: Phospho-proteomics, Concentration Assay, Inhibition, Cell Culture, Control, Western Blot, Incubation

Journal: Acta Biochimica et Biophysica Sinica

Article Title: SY-707, an ALK/FAK/IGF1R inhibitor, suppresses growth and metastasis of breast cancer cells

doi: 10.3724/abbs.2022008

Figure Lengend Snippet: Anti-tumor activities of SY-707 in breast cancer xenografts Xenograft tumors were established by inoculating T47D (A, B, C) cells or 4T1 (D) cells into the nude mice. Oral administration of SY-707 alone or combined with paclitaxel was initiated when tumors reached an average of approximately 150–300 mm3 in volume and continued through the experiment. Tumor volume was measured on the indicated days with the mean tumor volume±SD indicated for each group (10 mice/group). Each treatment group was compared to vehicle group with t-test. *P<0.05, **P<0.01. (B) The tumor tissues were harvested at 2 h after the last dosage of SY-707, compound levels in tumor tissues or plasma and the phosphorylation levels of FAK were analyzed.

Article Snippet: Primary antibodies against phospho-FAK (3283, 1:1000 dilution), phospho-ERK (4377, 1:2000 dilution), phospho-AKT (4060, 1:2000 dilution), FAK (3285, 1:1000 dilution), AKT (6703, 1:1000 dilution) and β-Actin (5125, 1:10,0000 dilution) were purchased from Cell Signaling Technology (Beverly, USA) and the HRP-conjugated goat anti-rabbit IgG (ZDR-5306, 1:10,000 dilution) was purchased from Jackson (West Grove, USA ).

Techniques: Clinical Proteomics, Phospho-proteomics